![\"Have](\"https:\/\/d1v1e13ebw3o15.cloudfront.net\/data\/91705\/pool_and_spa_master\/..jpg\" "\\"Have")
<\/p>\n<\/p>\n
Affecting millions of hospitalised patients across the world each year, sepsis occurs when the body\u2019s immune response to an infection attacks and injures its own tissues and organs.\u00a0Now, after promising results from a Phase 2 clinical trial in China of a sepsis drug candidate, Griffith University<\/a> researchers are looking to progress to a Phase 3 trial; the drug of which, in the words of one of its co-developers \u2014 Distinguished Professor Mark von Itzstein AO<\/a> \u2014 is believed to hold the potential for \u201csaving millions of lives\u201d.<\/p>\n Distinguished Professor Mark von Itzstein AO. Source: Griffith University<\/p>\n The drug, STC3141, is carbohydrate-based and was developed by von Itzstein and his team from Griffith\u2019s Institute for Biomedicine and Glycomics<\/a>, and Professor Christopher Parish<\/a> and his team at the Australian National Universi<\/a>ty. \u201cThe trial met the key endpoints to indicate the drug candidate was successful in reducing sepsis in humans,\u201d von Itzstein said.<\/p>\n Administered as an infusion via a cannula, STC3141 was found to counteract a significant biological molecule release phenomenon, which occurred in the body during the course of sepsis \u2014 the small-molecule experimental drug serving as a potential treatment for sepsis by reversing organ damage.<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/au\/wp-content\/uploads\/2026\/01\/Glycomics-2021-LM-7186_Mark.jpg.jpg\")
<\/p>\n